Genzyme, the maker of drugs for rare genetic diseases, said today it has started enrolling patients in a study of patients with mild Fabry disease to see if a low dose of Fabrazyme will help. Data from the study could enable the company to apply for expanded approval of the drug for early treatment of the disease, the Cambridge, MA-based company (NASDAQ: [[ticker:GENZ]]) said in a statement. Fabry disease is a hereditary condition related to a defective X chromosome, and affects about 5,000 patients in the world, Genzyme says. Sales of the product grew 21 percent in the second quarter, to $126.6 million.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
